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Available online 7 May 2016Misdiagnosis of lung cancer remains a serious problem due to the difﬁculty of distinguishing lung cancer from
other respiratory lung diseases. As a result, the development of serum-based differential diagnostic biomarkers
is in high demand. In this study, 198 clinical serum samples from non-cancer lung disease and lung cancer
patients were analyzed using nLC-MRM-MS for the levels of seven lung cancer biomarker candidates. When
the candidates were assessed individually, only SERPINEA4 showed statistically signiﬁcant changes in the
serum levels. TheMRMresults and clinical informationwere analyzedusing a logistic regression analysis to select
model for the best ‘meta-marker’, or combination of biomarkers for differential diagnosis. Also, under consider-
ation of statistical interaction, variables having low signiﬁcance as a single factor but statistically inﬂuencing on
meta-marker model were selected. Using this probabilistic classiﬁcation, the best meta-marker was determined
to be made up of two proteins SERPINA4 and PON1 with age factor. This meta-marker showed an enhanced dif-
ferential diagnostic capability (AUC=0.915) for distinguishing the two patient groups. Our results suggest that a
statistical model can determine optimal meta-markers, which may have better speciﬁcity and sensitivity than a
single biomarker and thus improve the differential diagnosis of lung cancer and lung disease patients.
Biological signiﬁcance:Diagnosing lung cancer commonly involves the use of radiographic methods. However, an
imaging-based diagnosis may fail to differentiate lung cancer from non-cancerous lung disease. In this study, we
examined several serum proteins in the sera of 198 lung cancer and non-cancerous lung disease patients by
multiple-reaction monitoring. We then used a combination of variables to generate a meta-marker model that
is useful as a differential diagnostic biomarker.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Lung cancer still presents high levels of mortality in cancer-related
deaths [1]. Currently, lung cancer diagnosis largely depends on clinical
imaging methods such as radiography, computed tomography (CT)
and positron emission tomography (PET). However, these technologies
are often incapable of distinguishing lung cancer fromother lung abnor-
malities due to poor speciﬁcity [2]. Lesions from non-cancerous lung
diseases can cause interference with solid tumor detection in imaging-
based diagnosis, in which case only biopsy can deﬁnitively diagnose
lung cancer [3]. To overcome the current problems involved in diagnos-
ing lung cancer apart from other respiratory diseases, the development
of feasible, molecular marker-based differential diagnostic methods is
highly desirable.
Several biochemical diagnostic molecules, called biomarkers, have
been discovered from serum, allowing simple and non-invasive diagno-
sis. Several protein biomarkers are already used in the clinics formistry, College of Veterinary
ak-gu, Seoul, 151-742, Korea.
. This is an open access article underscreening ormonitoring therapy response, such as PSA for prostate can-
cer, CA125 for ovarian cancer, CA19-9 for pancreatic cancer, and CEA for
colon cancer [4]. Much research has been conducted in hopes of ﬁnding
lung cancer diagnostic biomarkers in bodyﬂuids. At the present time, no
biomarkers which discovered by proteomics are FDA-approved and
used in clinical ﬁelds, [5–7] and no biomarker has been developed for
the differential diagnosis of lung cancers from other lung diseases.
Numerous biomarker candidates for lung cancer diagnosis have
been discovered and reported from our lab and other labs. However,
these biomarkers have never been tested as tools for the differential
diagnosis of lung cancers and other lung diseases. For this purpose,
discovered biomarker candidates should be validated on large scale
using clinical samples. Conventional methods for validation, such as
enzyme-linked immunosorbent assay (ELISA), immunohistochemistry
(IHC), and western blotting, are based on immuno-afﬁnity, which
require costly antibodies for each biomarker. In contrast, nano-ﬂow
liquid chromatography multiple-reaction monitoring mass spectrome-
try (nLC-MRM-MS) coupled with stable isotope dilution (SID) is the
most widely used MS-based, antibody-free technology for quantifying
multiple proteins with high-sensitivity, high-speciﬁcity, and high-
reproducibility [8–11]. In this large-scale validation process, it isthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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without additional enrichment or pre-fractionation of samples. In
addition, because no single marker is signiﬁcantly differentially
expressed in sera from lung cancer patients, focusing on the combina-
tion of two or more variables under consideration of statistical interac-
tion would be particularly valuable for improving the differential
diagnosis of lung cancer and other lung diseases [12].
In this study, 198 serum samples from patients with non-cancerous
lung disease or lung cancer were subjected to nLC-MRM-MS to analyze
the levels of multiple lung cancer biomarker candidates. Comparison of
a panel of marker combinations using logistic regression generated
meta-markers with improved capabilities for differential diagnosis of
lung cancer from other lung diseases.2. Material and methods
2.1. Sample collection
Serum samples from lung disease patients and lung cancer patients
were obtained at Asan Medical Center (Table 1). Ninety nine serum
samples of non-cancerous lung disease patients, who visited Asan
Medical Center, department of pulmonology and critical care medicine,
were collected from May 2011 to April 2013, and similarly ninety nine
serum samples from lung cancer patients, who visited Asan Medical
Center, department of pulmonology and critical care medicine, were
collected from March 2012 to February 2013. All serum samples were
collected using a serum-separating tube (SST). The SSTs were
centrifuged to separate the serum from whole blood within 24 h after
venipuncture. Samples were stored at−70 °C until analysis. Informed
consent was obtained from all donors (IRB 2011–0076).2.2. Sample preparation; in-solution tryptic digestion
Serum samples were diluted 20-fold with HPLC-grade water
(Honeywell Burdick & Jackson, Muskegon, MI). The protein concentra-
tion of diluted serum was measured using Quick Start™ Bradford 1×
Dye Reagent (Bio\\Rad Laboratories, Hercules, CA). Then, 30 μg of pro-
tein was prepared in 50mM ammonium bicarbonate and denatured by
boiling at 100 °C for 20 min. Dithiothreitol (Bio\\Rad Laboratories,
Hercules, CA) and iodoacetamide (Sigma-Aldrich, St Louis, MO) were
added for reduction and alkylation, both at a concentration of 10 mM.
Trypsin (Roche, Mannheim, Germany) was added to samples at a
protein-to-enzyme ratio of 50:1 (w/w) and incubated at 37 °C for
16 h. The digested peptide mixtures were cleaned using Pierce C18
spin column (Thermo Scientiﬁc, Rockford, IL, USA) according to the
manufacturer's instructions, dried, and stored at−20 °C until analysis.
Dried tryptic digests were resuspended in 30 μL of 0.1% formic acid for
mass spectrometric analysis.Table 1
Clinical information of serum samples.
Training set
Lung disease
Population 30
Age 57 (33–82)
Sex (male/female) 17/13
Disease diagnosis (TB/PN/ND/etc.) 3/12/9/6
Cancer types
Carcinoid tumor
NSCLC (1/2/3/4)
SCLC (LD, ED)
Smoking history (Curr, Ex, Non) 6/10/14
Abbreviations used: TB; tuberculosis, PN; pneumonia, ND; nodule, NSCLC; non-small cell lung ca
smoker, Ex; ex-smoker, Non; non-smoker.2.3. Target peptide selection
Tryptic target peptides were selected using the Skyline program
(64-bit, Version 1.4.0.4421) (MacCoss Laboratory, University of
Washington, Seattle,WA). Peptides containingNXT/NXS andRP/KPmo-
tifs were excluded, and peptides with lengths of 7 to 24 amino acids
were selected. Carbamidomethyl cysteine structural modiﬁcations
were included. To select proteotypic peptides, unique peptides were
sorted using Uniprot human database (2012.11 released version). To
select easily detectable peptides by nLC-MRM-MS, the NIST Q-Tof
database was also used as a reference. Stable isotope synthetic peptides
used in this study are as follows: β-Galactosidase; LNVENPK, AHGS;
EHAVEGDCDFQLLK, ITIH1; LDAQASFLPK, CLUS; ASSIIDELFQDR (JPT
Peptide Technologies GmbH, Berlin, Germany), SERPINA4;
GDATVFFILPNQGK, PON1; YVYIAELLAHK (21st Century Biochemicals,
MA, USA).
2.4. nLC-MRM-MS analysis
Liquid chromatography was conducted using a 1260 Inﬁnity LC sys-
tem with Chip Cube (Agilent technologies, Santa Clara, CA). The tryptic
digest was separated in HPLC-Chip, which consisted of a 40 nL enrich-
ment column and a 75 μm × 150 mm analytical column packed with
300 Å C18. Separation was performed using binary gradients with
buffers A (HPLC-grade water in 0.1% formic acid solution) and B (aceto-
nitrile in 0.1% formic acid solution). The columnwas initially equilibrat-
ed and eluted at a ﬂow rate of 0.4 μL/min for the nano-ﬂow pump and
4 μL/min for the capillary-ﬂow pump. The 30-min LC schedule with
14-min gradientwas programmed as follows: 1–15min, 3–40% B for re-
verse phase separation; 15–18min, 40–80% B to wash the chip column;
ﬁnally, 12 min in 3% B to equilibrate the chip column prior to the injec-
tion of the next sample.
A triple quadruple mass spectrometer (6490 Agilent technologies,
Santa Clara, CA) was used with the following parameters: positive ion
mode, a drying gas ﬂow rate of 11 L/min at 150 °C, and MS1 and MS2
set to unit resolution. For relative quantiﬁcation of 60 sera, dynamic
MRMwas conducted with a cycle time set to 500ms, and theminimum
andmaximum dwell times were 19.36 and 198.55 ms, respectively. For
SID-MRM validation of sera, dynamic MRM was conducted with cycle
time of 500 ms, and the minimum and maximum dwell times were
18.16 and 123.12 ms, respectively. Delta retention time was 4 min.
The data were visualized by Skyline (64-bit, Version 1.4.0.4421)
(MacCoss Laboratory, University of Washington, Seattle, WA).
2.5. Statistical analysis
Normalized MRM data were statistically analyzed using the T-test,
and P b 0.05 was considered statistically signiﬁcant. Combinations of
markers were analyzed using the binary logistic regression. All of the
analyses were performed using SPSS Statistics 23 (IBM Corp., NY, USA).Validation set
Lung cancer Lung disease Lung cancer
30 69 69
61.8 (25–80) 56.8 (27–79) 60.4 (30–75)
21/9 40/29 45/24
14/20/17/18
0 1
11/2/5/4 29/10/7/15
8/0 7/0
14/6/10 18/18/33 21/21/27
ncer, SCLC; small cell lung cancer, LD; limited disease, ED; extensive disease, Curr; current-
Fig. 1. Schematic diagram of overall workﬂow.
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3.1. Target screening for differential diagnosis of lung cancer and other lung
diseases
To study biomarker combinations using targeted proteomics, the
targets were selected from previous studies, and the analytic conditions
were optimized (Fig. 1). Fifteen potential single biomarkerswere select-
ed from our previous lung cancer biomarker study [13] and a publica-
tion from another research group, which analyzed secretome of 23
cancer cell lines (Supplementary Table 1) [14].
Relative quantiﬁcation using MRM was conducted, and the data
were normalized to the LNVENPK SIS-peptide derived from β-
galactosidase of Escherichia coli, which had been used as an internal
standard. A training set of human serum samples consisting of 30
cases of non-cancerous lung diseases (LD) and 30 cases of lung cancer
(LC), which are subsets of total 198 samples, were subjected to MRM
analysis (S1 Figure). Eight target proteins showed signiﬁcant differences
between serum samples of LD and LC in the MRM analysis (P b 0.05)
(Fig. 2). All but one candidate marker (CLUS) were observed to be
down-regulated in LC compared to LD.
3.2. SID-MRM development for selected biomarker candidate
To quantify biomarker candidate proteins using MRM methods in
clinical samples, the accuracy of the peptide quantiﬁcation must be
measured ﬁrst. To conﬁrm the precise quantitative accuracy of the
MRM performance, the stable isotope dilution (SID) technique was
used. Stable isotope-labeled standard (SIS)-peptides were tested at
several peptide concentrations to determine the optimal endogenous
detection ranges for each target [11]. SIS peptides were synthesized
with the stable isotope-labeled 13C and 15N incorporated at the C-
terminal lysine or arginine residue for the selected 8 protein candidates.
Then, the SIS-peptides were measured by MRM at a 50 femtomole per
microliter concentration to determine whether the peptides are
detectable in nLC-MRM-MS. The peptides corresponding to the selected
8 proteins C4BPA, C1R, AHGS, ITIH1, CLUS, SERPINA4, THBG and
PON1 are QSSSYSFFK, MDVFSQNMFCAGHPSLK, EHAVEGDCDFQLLK,
LDAQASFLPK, ASSIIDELFQDR, GDATVFFILPNQGK, FSISATYDLGATLLK
and YVYIAELLAHK, respectively. To establish quantiﬁcation methods
for these peptides, we performed collision energy optimization forselection of well-detected charge states and transitions to be measured
(S2 Fig. and S2 Table). QSSSYSFFK (C4BPA), MDVFSQNMFCAGHPSLK
(C1R), and FSISATYDLGATLLK (THBG) showed poor reproducibility in
liquid chromatography, and thus, these proteins were excluded from
further analysis.
Standard curves for the trypsin-digested crude sera were construct-
ed for the ﬁve SIS-peptides (S3 Figure). The sum of the total ion area
corresponded to the known quantities for each peptide. All analyses
were performed in triplicate. All standard curves showed good linearity
(0.93 b R2 b 0.99) when the SIS-peptides were spiked in crude sera.
3.3. SID-MRM analysis of selected targets in crude serum
Using developed SID-MRMmethods, seven targetswere validated in
sera from 99 non-cancerous lung disease patients (LD) and 99 lung
cancer patients (LC). The results showed that only one target protein
(SERPINA4) showed statistically signiﬁcant changes between LD and
LC (Fig. 3). SERPINA4 was signiﬁcantly lower (P b 0.001) in the sera of
lung cancer patients than in lung disease patients. However, other
target proteins did not show any signiﬁcant differences between the
two groups. To calculate the differential diagnostic power, ROC curves
were generated for each protein (Fig. 3). SERPINA4 had the highest
area-under-curve (AUC) values of 0.836, respectively (Fig. 3d).
3.4. Modeling for meta-marker generation
To improve the diagnostic power, wemade combinations of the can-
didate results using a logistic regression model. SID-MRM results from
30 samples from each group were used as a training set, and the other
69 data samples for each group were used as the test set. The quantita-
tive data of individual biomarkers had AUC-value differences between
the training set and the test set below 0.1 for all targets (Supplementary
Fig. 4).
The SERPINA4 result was signiﬁcant and had high AUC values (Fig.
3). Therefore, we combined the quantitative protein data and patient
clinical information with the SERPINA4-results to assess any potential
increase in diagnostic ability. We included statistical interactions for
variables with no signiﬁcance as single markers to generate the best
ﬁtting model. The estimated logistic regression statistic values for each
variable revealed age, PON1, and ITIH1 have signiﬁcant interactions
(Table 2). This strategy produced two types of models. The ﬁrst model
included PON1 (PON1, SERPINA4, age, SERPINA4*PON1, and
SERPINA4*age) (Table 3). The second model included ITIH1 (ITIH1,
SERPINA4, age, SERPINA4*ITIH1, and SERPINA4*ITIH1) (Supplementary
Table 3). However, the ITIH1 model showed a poor ﬁt in the logistic re-
gression (Supplementary Tables 4–6). Thus, we subsequently excluded
the ITIH1 model.
We next tested the equation using a validation data set to determine
if the PON1model is reliable. The results showed themodel correctly ﬁt
the data for both the training set and the validation set (Fig. 4).
4. Discussions
Diagnosis of lung cancer mainly relies on imaging technologies such
as radiography, CT, and PET scans. Radiography is convenient but has
low sensitivity. CT is commonly used as a lung cancer diagnostic meth-
od; however, it is not an ideal method due to radiation exposure and
cost. PET is the most sensitive of the three methods, but it is also the
most expensive. Biopsies, such as ﬁne needle aspiration (FNA), are the
most traditional and reliablemethod; however, biopsies are a highly in-
vasive procedure. With the primary use of imaging diagnostics, many
lung cancer patients are conﬂated with patients with lung-associated
symptoms. Many of the lung-associated symptoms, especially tubercu-
losis, pneumonia and lung nodules which are selected for this study, in-
terfere with the diagnosis of lung cancer in imaging-based diagnosis. In
this study, seven biomarker candidates were selected and validated as
Fig. 2.Relative quantitation on crude sera of a training set. (a)–(o) Quantiﬁcation results of eachbiomarker candidates in sera of non-cancer lung disease patients (N=30) and lung cancer
patients (N= 30). All of relative quantitation value was normalized by peak area of spiked LNVENPK peptide which derived from β-galactosidase.
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combination of SERPINA4, PON1 and age was shown to form the opti-
mal differential diagnostic meta-marker.
This study was designed for the validation of each protein marker
candidates and development of meta-marker model for the differential
diagnosis of lung cancer (LC) from other lung diseases (LD). Therefore,
sample set was made up non-cancerous lung disease and lung cancer
patients without healthy population. To verify the meta-marker
generated is statistically reliable, LD group and LC group are designed
to be composed of equal numbers.
Alongwith the development of high-throughput technologies,many
studies have reported biomarker candidates. However, validating the
candidates in large scale samples is still considered to be a hurdle for
biomarker development. Large-scale clinical validation is highly difﬁcult
due to the number of targets and samples.
Traditional immunoassay-based quantitative methods are suitable
for single biomarker validation, making it inappropriate to multiplex
marker validation. MS-based assay is sufﬁciently cost-effective than
immunoassay when the analysis is performed to multiplex biomarkers.
Even with current price of stable isotope labeled internal standard
and MS machine, it makes MRM assay costs highly competitive incomparison to current cost in the clinical immunoassays operated by
clinical hospital laboratory [15–18].
Nano-ﬂow MRM, an MS-based quantitative proteomics technology,
provides simultaneous validation with high sensitivity with a little
amount of sample, however, compared to standard-ﬂowMRMunstable
reproducibility should be optimized [8–11]. Therefore, SIS-peptide as an
internal standard should be spiked for accurate quantitative analysis.
Considering cost effectiveness, relative quantiﬁcation using global
standards (in this study, the LNVENPK synthetic peptide derived from
β-galactosidase was used) is possible, which provides high productivity
in multi-target screens.
When protein quantitative analysis using mass spectrometer were
performed, selection of unique peptide derived from a protein is impor-
tant. Especially, hydrophobic and/or high reactivity amino acid compo-
sition of peptide is inﬂuential factor to liquid chromatography. For
example, three peptides derived fromC4BPA, C1R and THBP are exclud-
ed because they are composed at least 30% hydrophobic amino acid
and/or methionine, a highly oxidative residue.
To closely reﬂect clinical environment, minimal sample preparation,
without abundant serum protein depletion or pre-fractionation, is a
valid approach, if detectable range of nLC-MRM-MS is considered. The
Fig. 3. SID-MRM validation of selected targets in crude sera. SID-MRM analysis showed that (d) SERPINA4 was signiﬁcantly lower in lung cancer patients (LC; n= 99) compared to lung
disease patients group (LD; n= 99) (P b 0.05). The other proteins, (a)–(c) and (e) had no statistical difference between two groups.
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(152.36 μg/mL), SERPINA4 (22.1 μg/mL), and PON1 (59.3 μg/mL) are
reported in human blood [19–21]. Also, when Agilent 6490 mass
spectrometer coupled with standard-ﬂow ESI was used to quantify the
proteins in human crude plasma samples, lower limit of quantitation
(LLOQ) is reported to be 751 ng/mL. Considering Agilent 6490 coupledTable 2
Estimated logistic regression statistic values in training set.
Score Sig.
SERPINA4 12.597 0.0004
Age 2.468 0.116
PON1 0.567 0.452
CLUS 6.048 0.014
AHSG 6.971 0.008
ITIH1 1.736 0.188
C1R 0.179 0.672
Smoking 3.293 0.070
Sex 1.148 0.284
SERPINA4 by Age 5.786 0.016
SERPINA4 by PON1 3.988 0.046
SERPINA4 by CLUS 2.723 0.099
SERPINA4 by AHSG 0.460 0.498
SERPINA4 by ITIH1 3.858 0.050
SERPINA4 by C1R 2.836 0.092
SERPINA4 by Smoking 0.349 0.555
SERPINA4 by SEX 0.107 0.744
Abbreviations used: Sig, signiﬁcance.with nano-ﬂow ESI was used in this study, direct detection of target
peptide/protein by nLC-MRM-MS is appropriate [22].
Despite vast numbers of biomarker studies in past two decades,
there remains no approved valid differential diagnostic biomarker for
lung cancers [23,24]. Currently, there is no reliable blood biomarker
for differential diagnosis of lung cancer from other lung diseases. Previ-
ous studies have focused on single biomarkers. However, there are
known technological limitations associatedwith identifying biomarkers
within a complex biological system such as cancer because there are
multiple differentially expressed proteins. The limitation of a single pro-
tein biomarker could be overcome by combining multiple marker
panels to form a meta-marker with improved diagnostic value via
weighting on signiﬁcant marker, considering interaction, and compen-
sate quantitation errors. Statistical models including logistic regression
enables the selection of meta-markers that show improved diagnostic
power [25].
Logistic regression has been used in clinical statistics to estimate
causes of disease and in analyses of combinations of multi-marker
panels [26,27]. Logit, which derives from logistic regression as a repre-
sentative value, is deﬁned as the log-value of (probability/1-probabili-
ty). In this study, positive logit values imply a diagnosis of cancer and
negative logit values imply non-cancerous lung disease. The meta-
marker presented in this study is a combination result based on this lo-
gisticmodel, which functionswell in distinguishing lung cancer patients
from non-cancerous lung disease patients. Currently, low-dose CT is
used and reported to be effective for lung cancer screening. Considering
Table 3
Logistic regression analysis for PON1, SERPINA4, and age included modeling in training set.
Beta Std. error Wald Sig. Odd ratio 95% CI for odd ratio
Lower Upper
SERPINA4 −4.760 19.275 0.061 0.805 8.569.E−03 3.359.E−19 2.186.E+14
Age 0.155 0.143 1.178 0.278 1.168.E+00 8.826.E−01 1.544.E+00
PON1 47.400 18.004 6.932 0.008 3.849.E+20 1.823.E+05 8.129.E+35
SERPINA4 by Age −0.220 0.270 0.659 0.417 8.029.E−01 4.726.E−01 1.364.E+00
SERPINA4 by PON1 −19.302 28.175 0.469 0.493 4.141.E−09 4.307.E−33 3.981.E+15
Constant −11.202 10.235 1.198 0.274 1.365.E−05
Abbreviations used: SE, standard error; Sig., signiﬁcance; CI, conﬁdence interval.
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developed in this study show better false positive rate (2/69) [28].
Our results demonstrated that only the signiﬁcant variables are
needed for themarker panel. However, a superﬁcial relationship combi-
nation could miss complex biological interactions. These interactions
may explain biological phenomena more accurately. In this study, the
quantitative data from ﬁve proteins and the patient clinical information
were used to produce a high quality model. Through these consider-
ations, the biomarker candidates lacking signiﬁcant results (PON1,
age) as single markers were found to have signiﬁcant positive effects
on the meta-marker function. The logistic model maximizes the
cooperative effect using optimum weighting to elucidate the value of
each variable. In conclusion a meta-marker by the PON1, SERPINA4,
and age combination is the most potent differential meta-marker with
a suitable number of proteins [29].
Serpin peptidase inhibitor, clade A, member 4 (SERPINA4) is known
as a serine protease inhibitor and heparin-binding protein. SERPINA4
regulates angiogenesis, inﬂammatory reactions, and blood pressure
[30–33]. SERPINA4 inhibits vascular endothelial growth factor (VEGF)Fig. 4.Differential diagnostic capability of biomarker combinations in both the training set and v
the combination was applied to validation set (b).or basic ﬁbroblast growth factor (bFGF)-induced angiogenesis and
tumor growth [34,35]. Because of its anti-tumor effect via anti-
inﬂammatory and anti-angiogenic activity, SERPINA4 has been studied
as a potential therapeutic in laboratory trials [30–32,36]. At this point,
the results indicating a down-regulation of SERPINA4 in lung cancer
patient serum compared to other lung diseases are in accordance with
previously reported studies.
Serum paraoxonase 1 (PON1) is mainly expressed in the liver and is
secreted into the blood. PON1 is hydrolytic enzyme that processes
organophosphate substrates and is associated with high density lipid
(HDL [37]. It has been suggested that PON1 protects cells against lipid
oxidation, but the antioxidant mechanism remains unknown [29]. In
our previous study, PON1 was found in decreased levels in the sera of
small cell lung cancer (SCLC); reversely, the degree of PON1
fucosylationwas increased [38]. The down-regulation of PON1 in cancer
is also reported with endometrial, ovarian, pancreatic, and other lung
cancers [39–42]. This study showed that the non-cancerous lung
disease patients had further decreased levels of PON1 compared to
lung cancer patients. It is also reported that PON1 activity wasalidation set Themodel built based on SERPINA4, PON1 and Age in the training set (a) and
42 Y.-I. Kim et al. / Journal of Proteomics 148 (2016) 36–43signiﬁcantly lower in pulmonary tuberculosis than normal individuals
[43]. Larger-scale validation with a normal group included or
antioxidant-related target validation may help explain why PON1 ap-
pears at even lower levels in the lung disease group in comparison
with the lung cancer group.
In conclusion, this study presents meta-markers for the differential
diagnosis of lung cancer and non-cancerous lung diseases. These
meta-markers were determined by calculated values obtained from lo-
gistic regression models under consideration of statistical interaction.
The meta-markers are combinations of data about not only protein
levels as measured by MRM but also clinical information, and have the
potential to enhance the differential diagnostic power between lung
cancers and other lung diseases.
5. Conclusions
In this study, we attempted to ﬁnd the best meta-marker by the
combination of the MRM quantitative values from a panel of pro-
teins. Our results showed that a meta-marker combination of
SERPINA4, PON1 and age improved sensitivity and speciﬁcity when
used together as a biomarker for the differential diagnosis between
lung cancers and non-cancerous lung diseases, even PON1 did not
show signiﬁcance as a single bio signature. The results thus indicate
that the combination of several potential biomarkers, determined via
modeling under consideration of statistical interaction, would likely
provide better diagnostic speciﬁcity and sensitivity than a single bio-
marker for the differential diagnosis between lung cancer and lung
disease patients.
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